Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
This article was originally published in The Pink Sheet Daily
Executive Summary
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.
You may also be interested in...
Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News
Robert Armstrong, VP, Global External R&D at Eli Lilly is entrusted with perhaps the most challenging task in his organization - cherry-picking the best research partners to help enrich Lilly's pipeline of future drugs - yet keep costs on those multiple research projects as low as possible. Armstrong, who has struck many deals with Indian firms including a joint venture with Jubilant, advocates openness in communication with his partners, but said in an interview with PharmAsia News' India bureau that overcoming challenges and reaching targeted milestones is the true test for strong partnerships.
Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from his top job in U.S.-based Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
Lilly and Merck Lead the Way With Asian FIPNet Strategies
There's a new acronym to learn:FIPNet--for fully integrated pharmaceutical network. Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality research available in India and China--countries that also should prove to be a major source of future customers. Merck and Eli Lilly are two companies leading the FIPNet charge.